Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIAsk in your own words. Each question is answered independently.
Select a question to fill the editor, then ask it or make it your own.
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
| Stem definition | Drug id | CAS RN |
|---|---|---|
| class III antiarrhythmics | 1412 | 122647-31-8 |
| Dose | Unit | Route |
|---|---|---|
| 1 | mg | P |
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
| S (Water solubility) | 100 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
| EoM (Fraction excreted unchanged in urine) | 7 % | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 0.34 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BA (Bioavailability) | 8 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| Vd (Volume of distribution) | 12 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 26 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.60 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 7 hours | Lombardo F, Berellini G, Obach RS |
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Dec. 28, 1995 | FDA | PHARMACIA AND UPJOHN |
None
None
None
None
| Source | Code | Description |
|---|---|---|
| ATC | C01BD05 | CARDIOVASCULAR SYSTEM CARDIAC THERAPY ANTIARRHYTHMICS, CLASS I AND III Antiarrhythmics, class III |
| FDA EPC | N0000175426 | Antiarrhythmic |
| MeSH PA | D000889 | Anti-Arrhythmia Agents |
| MeSH PA | D002317 | Cardiovascular Agents |
| CHEBI has role | CHEBI:38070 | anti-arrhythmia drug |
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Cardioversion of Atrial Flutter | indication | ||
| Cardioversion of Atrial Fibrillation | indication | ||
| Torsades de pointes | contraindication | 31722008 | |
| Hypokalemia | contraindication | 43339004 | |
| Bradycardia | contraindication | 48867003 | |
| Prolonged QT interval | contraindication | 111975006 | |
| Hypomagnesemia | contraindication | 190855004 | |
| Heart block | contraindication | 233916004 | |
| Congenital long QT syndrome | contraindication | 442917000 |
None
None
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 10.03 | acidic |
| pKa2 | 9.4 | Basic |
None
None
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Potassium voltage-gated channel subfamily H member 2 | Ion channel | BLOCKER | IC50 | 8 | CHEMBL |
| ID | Source |
|---|---|
| 4024018 | VUID |
| N0000022023 | NUI |
| D00648 | KEGG_DRUG |
| 122647-32-9 | SECONDARY_CAS_RN |
| 4020956 | VANDF |
| 4024018 | VANDF |
| C0082966 | UMLSCUI |
| CHEBI:5856 | CHEBI |
| CHEMBL533 | ChEMBL_ID |
| DB00308 | DRUGBANK_ID |
| CHEMBL2355456 | ChEMBL_ID |
| C067192 | MESH_SUPPLEMENTAL_RECORD_UI |
| 60753 | PUBCHEM_CID |
| 7200 | IUPHAR_LIGAND_ID |
| 6642 | INN_ID |
| 2436VX1U9B | UNII |
| 41289 | RXNORM |
| 169546 | MMSL |
| 4863 | MMSL |
| d03871 | MMSL |
| 005740 | NDDF |
| 005741 | NDDF |
| 108491000 | SNOMEDCT_US |
| 108492007 | SNOMEDCT_US |
| 372500009 | SNOMEDCT_US |
| 2436VX1U9B | INXIGHT DRUGS |
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Corvert | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0009-3794 | INJECTION, SOLUTION | 0.10 mg | INTRAVENOUS | NDA | 25 sections |
| Corvert | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0009-3794 | INJECTION, SOLUTION | 0.10 mg | INTRAVENOUS | NDA | 25 sections |
| Ibutilide Fumarate | Human Prescription Drug Label | 1 | 23155-326 | INJECTION, SOLUTION | 1 mg | INTRAVENOUS | ANDA | 20 sections |
| Ibutilide Fumarate | Human Prescription Drug Label | 1 | 23155-326 | INJECTION, SOLUTION | 1 mg | INTRAVENOUS | ANDA | 20 sections |